<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01796132</url>
  </required_header>
  <id_info>
    <org_study_id>SSRI-Milk</org_study_id>
    <secondary_id>320030_135650</secondary_id>
    <secondary_id>2012-004509-29</secondary_id>
    <nct_id>NCT01796132</nct_id>
  </id_info>
  <brief_title>Antidepressants During Pregnancy and Lactation: Pharmacokinetics and Clinical Implications</brief_title>
  <official_title>Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: The childbearing years are a time of increased vulnerability to the onset of mood
      disorders in women and a high prevalence of exposure to antidepressant drugs during pregnancy
      and postpartum has been reported. However, the lack of information regarding the milk
      transfer and the safety of these drugs in breastfed infants and the related fear of adverse
      events for the sucking infant are some of the factors responsible for stopping prematurely
      breast-feeding or avoiding drug therapy. Selective serotonin reuptake inhibitors (SSRI) and
      selective serotonin and noradrenaline reuptake inhibitors (SNRI) are the most frequently
      prescribed antidepressant drugs during pregnancy and the post-partum period. They exhibit a
      wide interpatient variability in their concentration profiles that has been related to
      numerous environmental, stereochemical, demographic and genetic influences that might alter
      the level of exposure of breastfed newborns. Limited information is available regarding the
      safety of use of these antidepressant drugs during lactation, and is generally derived from
      small studies. A comprehensive description of their distribution and quantification in milk
      in a larger cohort of patients under various influences and the resulting impact on milk
      concentrations is lacking.

      Objectives: The current proposal addresses the primary objectives of quantifying the range of
      concentration to citalopram, escitalopram, sertraline, fluoxetine, paroxetine, fluvoxamine,
      duloxetine and venlafaxine in mother plasma and breast milk in relation to genetic
      polymorphisms, stereochemistry, demographics and environmental factors in a large cohort of
      depressive mothers. This will enable to derive the exposure to the breast-fed child taking
      into account this variability and therefore better adjust treatment to potential influences.
      As secondary objectives, we will examine the neurodevelopmental outcome of a sub-set of
      infants subjected to SSRI/SNRI in utero and/or during breastfeeding at birth, 6, 18 and 36
      months, and compared to that of a control population of infants not subjected to this
      treatment.

      Expected Results: The proposed strategy will offer new information regarding the expected
      level of drug exposure associated with each or with a combination of risk factors and help
      for optimizing the security and rationalizing the use of antidepressant treatment in
      lactating women. Hence, research on the safety of use of these drugs for the developing child
      is an area of great public health significance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      see brief summary
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the pharmacokinetics of SSRI/SNRI antidepressant drugs in breast milk secretion</measure>
    <time_frame>week 1 and week 4-6 postpartum</time_frame>
    <description>The principal aim is to derive exposure to the breast-fed child by simulation while integrating influencing factors on pharmacokinetics (as genetic polymorphism, stereochemistry, demographics or environmental aspects).
5ml blood, 10ml fore-milk and 10ml hind-milk are taken from the mother during the same feed at week 1 and week 4-6 postpartum. Antidepressant drug concentrations are determined by LC-MS/MS and milk composition by human milk analyzer.Pharmacogenetic tests are performed with PCR-Taqman on maternal blood samples and cover genes involved in the metabolism (e.g CYP) and distribution (e.g. p-Gp) of antidepressants. Simulation of antidepressant drug secretion into breast milk will take into account all this information and will be performed with non-linear mixed effects modelling techniques.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Examine neonatal adaptation</measure>
    <time_frame>delivery and week 1 postpartum</time_frame>
    <description>The specific aim is to evaluate neonatal adaptation after in utero exposure to antidepressants and its relation to cord blood concentration.
5ml blood are taken from the umbilical cord and the mother at delivery. Antidepressant drug concentrations are determined by LC-MS/MS. Finnegan Score is used to evaluate the severity of possible withdrawal or discontinuation syndrome in exposed newborns.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examine neurodevelopment</measure>
    <time_frame>week 1, month 6, 18 and 36 postpartum</time_frame>
    <description>The specific aim is to evaluate neurodevelopment of a sub-set of infants exposed to any SSRI/SNRI in utero and/or during breastfeeding compared to a control population of infants not exposed to this treatment.
During week 1 postpartum, somatic and neurologic state of the newborn are evaluated by a pediatrician using routine measures as well as specific tools (Dubowitz's neurologic assessment, Prechtl's general movements). At month 6,18 and 36, neurodevelopment of the infants are assessed using Hammersmith Infant Neurological Examination and Bayley Scales of Infant Development III. At the same time, mother's mental well-being is determined by using self-administered questionnaires (Edinburgh Postnatal Depression Scale, State-Trait Anxiety Inventory, Parental Sens of Competence and Revised Infant Temperament Questionnaire).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study of growth</measure>
    <time_frame>birth, month 6, 18 and 36 postpartum</time_frame>
    <description>The specific aim is to evaluate growth of infants exposed to any of the SSRI/SNRI commercialized, compared to standardized growth charts.
Usual infant growth information (size, body weight, head circumference) are collected routinely at birth and month 6,18,36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examine early mother-infant relationship</measure>
    <time_frame>Month 6 postpartum</time_frame>
    <description>The specific aim is to explore the quality of early mother-infant relationship of a sub-set of infants whose mothers are treated with SSRI/SNRI, compared to that of a control population of infants not exposed to this treatment.
At month 6 postpartum, mother-infant relationship is evaluated by pedopsychiatrists using Care Index.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Depressive Disorder</condition>
  <condition>Lactation</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Pregnant and/or nursing mothers not taking a SSRI or SNRI antidepressant are recruited in a non-exposed group (Control or no SSRI/SNRI). Control group participates only in the sub-studies related to neonatal adaptation, neurodevelopment, growth and early mother-infant relationship.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SSRI/SNRI exposure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregnant and/or nursing mothers under SSRI or SNRI treatment are recruited in an exposed group (SSRI/SNRI exposure). Drug regimen including dosage, frequency and duration is not modified by the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SSRI/SNRI</intervention_name>
    <description>Exposed group of mothers taking one of the mentioned antidepressant drugs of the class of selective serotonin reuptake inhibitors (SSRI) or serotonin/noradrenalin reuptake inhibitors (SNRI).</description>
    <arm_group_label>SSRI/SNRI exposure</arm_group_label>
    <other_name>citalopram</other_name>
    <other_name>duloxetine</other_name>
    <other_name>escitalopram</other_name>
    <other_name>fluoxetine</other_name>
    <other_name>fluvoxamine</other_name>
    <other_name>paroxetine</other_name>
    <other_name>sertraline</other_name>
    <other_name>venlafaxine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients planning to deliver in the 5 maternities involved in the study;

          -  Mothers under treatment by any SSRI/SNRI (fluvoxamine, fluoxetine, paroxetine,
             duloxetine, citalopram, escitalopram, sertraline or venlafaxine);

          -  Mothers who intent to breastfeed their child;

          -  Ability to understand and willingness to sign a written informed consent document for
             plasma and milk withdrawal and pharmacogenetic testing.

          -  For the neurodevelopment follow-up part,all babies of the Maternity of Lausanne,
             Morges or Geneva exposed to SSRI/SNRI will be enrolled. A control group of infants of
             the same socio-economic status as the subset of exposed patients will be recruited in
             the Maternity Hospital of Lausanne.

        Exclusion Criteria:

          -  Mothers &lt;18 years of age patients;

          -  Infants of gestational age &lt; 34 weeks;

          -  Mothers giving birth to infants with major malformations;

          -  Inability to communicate due to language problems for the mother;

          -  Patients with a socio-economic context making close monitoring of the child by the
             mother or a relative not possible.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chantal Csajka, Prof PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois (CHUV)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chantal Csajka, Prof PhD</last_name>
    <phone>0041 21 314 42 63</phone>
    <email>chantal.csajka@chuv.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alice Panchaud, PhD</last_name>
    <phone>0041 21 314 42 76</phone>
    <email>alice.panchaud@chuv.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'Obstétrique, Service de Néonatologie; Centre Hospitalier Universitaire Nancy</name>
      <address>
        <city>Nancy</city>
        <state>Meurthe-et-Moselle</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Michel Hascoët, Prof MD</last_name>
      <email>jm.hascoet@maternite.chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Michel Hascoët, Prof MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Lamy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Obstétrique, Service de Néonatologie; Hospices civiles de Lyon (HCL)</name>
      <address>
        <city>Lyon</city>
        <state>Rhône</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Claris, Prof MD</last_name>
      <email>olivier.claris@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier Claris, Prof MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal Gaucherand, Prof MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Etienne Beaufils, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kim NGuyen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division de Pharmacologie Clinique, Service d'Obstétrique, Service de Néonatologie, Service de Pédopsychiatrie de liaison, Unité de Pharmacogénétique et Psychopharmacologie Clinique; Centre Hospitalier Universitaire Vaudois (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantal Csajka, Prof PhD</last_name>
      <email>chantal.csajka@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Chantal Csajka, Prof PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice Panchaud, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chin B Eap, Prof PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Francois Tolsa, Prof MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yvan Vial, MD MER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Myriam Bickle Graz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathilde Morisod Harari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Céline Fischer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Obstétrique, Service de Pédiatrie; Ensemble Hospitalier de la Côte (EHC)</name>
      <address>
        <city>Morges</city>
        <state>Vaud</state>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Rouiller, MD</last_name>
      <email>sylvie.rouiller@ehc.vd.ch</email>
    </contact>
    <investigator>
      <last_name>Sylvie Rouiller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Obstétrique, Service du Développement et de la Croissance; Hopitaux Universitaires Genevois (HUG)</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuella Epiney, MD</last_name>
      <email>manuella.epiney@hcuge.ch</email>
    </contact>
    <investigator>
      <last_name>Manuella Epiney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristina Borradori Tolsa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>McNamara PJ, Abbassi M. Neonatal exposure to drugs in breast milk. Pharm Res. 2004 Apr;21(4):555-66. Review.</citation>
    <PMID>15139511</PMID>
  </reference>
  <reference>
    <citation>Goldman AS, Hopkinson JM, Rassin DK. Benefits and risks of breastfeeding. Adv Pediatr. 2007;54:275-304. Review.</citation>
    <PMID>17918475</PMID>
  </reference>
  <reference>
    <citation>Marcus SM, Flynn HA, Blow FC, Barry KL. Depressive symptoms among pregnant women screened in obstetrics settings. J Womens Health (Larchmt). 2003 May;12(4):373-80.</citation>
    <PMID>12804344</PMID>
  </reference>
  <reference>
    <citation>Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol. 2004 Apr;103(4):698-709. Review. Erratum in: Obstet Gynecol. 2004 Jun;103(6):1344.</citation>
    <PMID>15051562</PMID>
  </reference>
  <reference>
    <citation>Poobalan AS, Aucott LS, Ross L, Smith WC, Helms PJ, Williams JH. Effects of treating postnatal depression on mother-infant interaction and child development: systematic review. Br J Psychiatry. 2007 Nov;191:378-86. Review.</citation>
    <PMID>17978316</PMID>
  </reference>
  <reference>
    <citation>di Scalea TL, Wisner KL. Pharmacotherapy of postpartum depression. Expert Opin Pharmacother. 2009 Nov;10(16):2593-607. doi: 10.1517/14656560903277202. Review.</citation>
    <PMID>19874247</PMID>
  </reference>
  <reference>
    <citation>Sie SD, Wennink JM, van Driel JJ, te Winkel AG, Boer K, Casteelen G, van Weissenbruch MM. Maternal use of SSRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation. Arch Dis Child Fetal Neonatal Ed. 2012 Nov;97(6):F472-6. doi: 10.1136/archdischild-2011-214239. Review. Erratum in: Arch Dis Child Fetal Neonatal Ed. 2013 Mar;98(2):F180.</citation>
    <PMID>23080479</PMID>
  </reference>
  <reference>
    <citation>Horstmann S, Binder EB. Pharmacogenomics of antidepressant drugs. Pharmacol Ther. 2009 Oct;124(1):57-73. doi: 10.1016/j.pharmthera.2009.06.007. Epub 2009 Jun 27. Review.</citation>
    <PMID>19563827</PMID>
  </reference>
  <reference>
    <citation>Baumann P, Eap CB. Enantiomeric antidepressant drugs should be considered on individual merit. Hum Psychopharmacol. 2001 Dec;16(S2):S85-S92.</citation>
    <PMID>12404713</PMID>
  </reference>
  <reference>
    <citation>Panchaud A, Garcia-Bournissen F, Csajka C, Kristensen JH, Taddio A, Ilett KF, Begg EJ, Ito S. Prediction of infant drug exposure through breastfeeding: population PK modeling and simulation of fluoxetine exposure. Clin Pharmacol Ther. 2011 Jun;89(6):830-6. doi: 10.1038/clpt.2011.23. Epub 2011 Apr 27.</citation>
    <PMID>21525869</PMID>
  </reference>
  <reference>
    <citation>Lobo ED, Quinlan T, O'Brien L, Knadler MP, Heathman M. Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation. Clin Pharmacokinet. 2009;48(3):189-97. doi: 10.2165/00003088-200948030-00005. Erratum in: Clin Pharmacokinet. 2011 Oct 1;50(10):687-8.</citation>
    <PMID>19385712</PMID>
  </reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2013</study_first_submitted>
  <study_first_submitted_qc>February 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2013</study_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Chantal Csajka</investigator_full_name>
    <investigator_title>Prof PhD</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Lactation</keyword>
  <keyword>Breastfeeding</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Antidepressant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

